» Articles » PMID: 25729475

Recent Advances in Dietary Supplementation, in Treating Non-alcoholic Fatty Liver Disease

Overview
Journal World J Hepatol
Specialty Gastroenterology
Date 2015 Mar 3
PMID 25729475
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Nonalcoholic fatty liver disease (NAFLD) is currently known as the most common liver problem, characterized by excessive lipid accumulation in hepatocytes, which may progress to other liver diseases such as nonalcoholic steatohepatitis, hepatic tissue fibrosis, liver cirrhosis, and failure or hepatocellular carcinoma. Since NAFLD is positively associated with the development of obesity, insulin resistance, and ultimately type 2 diabetes mellitus, it is often regarded as the hepatic manifestation of the metabolic syndrome. No pharmacologic treatment has yet been proven for this disease. For most patients with presumed or confirmed NAFLD, the only proven strategy is to offer lifestyle advice that can lead to sustained weight loss. Since insulin resistance, oxidative stress, inflammation, and necro-apoptosis are involved in NAFLD pathogenesis, it seems that every potential therapeutic agent should target one or some of these pathologic events. There are many well known anti-oxidants, anti-inflammatory, and insulin sensitizer dietary supplements which have shown beneficial effects on NAFLD improvement in animal and human studies. The purpose of this review is to explore the existing evidences on dietary supplements considered to have hepatoprotective properties, and to present some proposed mechanisms by which they may protect against NAFLD.

Citing Articles

Assessing clenbuterol's modulation of metabolic and inflammatory pathways in Nile tilapia (Oreochromas niloticous) fed high fat diet.

Rashwan A, Assar D, Salah A, Abualreesh M, Salem S, Althobaiti N Sci Rep. 2025; 15(1):1581.

PMID: 39794453 PMC: 11724019. DOI: 10.1038/s41598-024-84814-1.


Multifunctional role of oral bacteria in the progression of non-alcoholic fatty liver disease.

Mei E, Yao C, Chen Y, Nan S, Qi S World J Hepatol. 2024; 16(5):688-702.

PMID: 38818294 PMC: 11135273. DOI: 10.4254/wjh.v16.i5.688.


The effect of soy isoflavones supplementation on metabolic status in patients with non-alcoholic fatty liver disease: a randomized placebo controlled clinical trial.

Neshatbini Tehrani A, Hatami B, Daftari G, Hekmatdoost A, Yari Z, Salehpour A BMC Public Health. 2024; 24(1):1362.

PMID: 38773414 PMC: 11107053. DOI: 10.1186/s12889-024-18812-3.


The effect of soy isoflavones on non-alcoholic fatty liver disease and the level of fibroblast growth factor-21 and fetuin A.

Neshatbini Tehrani A, Hatami B, Helli B, Yari Z, Daftari G, Salehpour A Sci Rep. 2024; 14(1):5134.

PMID: 38429385 PMC: 10907727. DOI: 10.1038/s41598-024-55747-6.


The Potential Role of Gossypetin in the Treatment of Diabetes Mellitus and Its Associated Complications: A Review.

Naidoo K, Khathi A Int J Mol Sci. 2023; 24(24).

PMID: 38139436 PMC: 10743819. DOI: 10.3390/ijms242417609.


References
1.
Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A . Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr. 2014; 99(3):535-42. DOI: 10.3945/ajcn.113.068890. View

2.
Gossard A, Lindor K . Current therapies for nonalcoholic fatty liver disease. Drugs Today (Barc). 2012; 47(12):915-22. DOI: 10.1358/dot.2011.47.12.1688530. View

3.
Pacana T, Sanyal A . Vitamin E and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care. 2012; 15(6):641-8. PMC: 4984672. DOI: 10.1097/MCO.0b013e328357f747. View

4.
Akcam M, Boyaci A, Pirgon O, Kaya S, Uysal S, Dundar B . Therapeutic effect of metformin and vitamin E versus prescriptive diet in obese adolescents with fatty liver. Int J Vitam Nutr Res. 2012; 81(6):398-406. DOI: 10.1024/0300-9831/a000086. View

5.
Firenzuoli F, Gori L . Herbal medicine today: clinical and research issues. Evid Based Complement Alternat Med. 2008; 4(Suppl 1):37-40. PMC: 2206236. DOI: 10.1093/ecam/nem096. View